Publications by authors named "Mark J Latten"
Article Synopsis
- This study focused on predicting how rheumatoid arthritis (RA) patients would respond to anti-tumor necrosis factor alpha (anti-TNFα) drugs by examining specific genetic variants.
- Researchers collected blood samples from 238 RA patients and used advanced genetic testing methods to analyze the influence of various genetic markers on treatment response.
- It was found that certain genetic variations, particularly the MTHFR1 variant and HLA-DRB1*0404 allele, were linked to better treatment responses, helping to identify patients who might benefit the most from anti-TNFα therapies.
Purpose Of Review: Familial hypercholesterolaemia is a hereditary disorder of lipoprotein metabolism which causes a lifelong increase in LDL-C levels resulting in premature coronary heart disease. The present review looks at some of the recent literature on how molecular methods can be used to assist in the definitive diagnosis of familial hypercholesterolaemia in a range of patient groups.
Recent Findings: Several recent studies have shown that the prevalence of clinical familial hypercholesterolaemia is higher than previously thought at 1/200 to 1/300, and that 2-5% of patients presenting with early myocardial infarction can be found to have a familial hypercholesterolaemia mutation.
Background Detection of disease-associated mutations in patients with familial hypercholesterolaemia is crucial for early interventions to reduce risk of cardiovascular disease. Screening for these mutations represents a methodological challenge since more than 1200 different causal mutations in the low-density lipoprotein receptor has been identified. A number of methodological approaches have been developed for screening by clinical diagnostic laboratories.
View Article and Find Full Text PDF